mk-8237
FDA accepts biologics license application for MSD’s allergy immunotherapy drug
April 13, 2016Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
